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PRINCIPLES
The photodynamic effect requires the presence of a chemical photosensitizer, light of appropriate wavelength and oxygen. The principle of the therapy is that energy (absorbed as light via the intracellular photosensitizer) is transferred to oxygen molecules which then form highly reactive intermediaries (Figure 1 ). The short half-life of such reactive oxygen species (< 1 ps) explains the very localized nature of the effect; and the modest energy requirement means that hyperthermia, and hence damage to adjacent organs, is unlikely.
Photodynamic therapy has several potential advantages over conventional treatments. The main attraction is the lack of scarring since connective tissues, including collagen and elastin, tend to be unaffectedl ( Figure 2 clinicians. In addition, with earlier sensitizers, skin photosensitivity lasting several weeks limited its acceptability. Newer photosensitizers and improvements in light delivery have simplified therapy, and a major advance has been the development of powerful, low-cost, portable nonlaser light sources3. Although at present these cannot be directed into monofilament optical fibres (<1 mm), they are replacing lasers for photodynamic therapy of skin lesions.
PHOTODYNAMIC DETECTION
For detection of disease, the use of short wavelength light (i.e. blue or ultraviolet) allows the identification of abnormal areas by fluorescence. 5-aminolaevulinic acid (ALA), a precursor of the haem biosynthetic pathway, is increasingly being used for photodynamic detection because of its local conversion into natural photosensitizers. ALA is selectively taken up by dysplastic and malignant mucosa4 and this property has been exploited in the diagnosis of nonvisible carcinoma-in-situ of the bladder5, the detection of early stage lung cancer6, the intraoperative assessment of resection margins in glioma surgery7 and nephron-sparing surgery for renal cell carcinoma8.
PHOTODYNAMICTHERAPY
Superficial epidermal/mucosal lesions For treatment of skin lesions the sensitizer is usually ALA, because this agent can be given topically and localizes to mucosal and epidermal layers. Photodynamic therapy is an attractive option because conventional surgery and radiotherapy can cause troublesome skin contraction, scarring and ulceration, especially in multiple or extensive disease; moreover, areas with low skin laxity and poor vascularity (e.g. the bridge of the nose and the anterior tibial area) often require skin grafting. ALA photodynamic therapy for superficial lesions including basal cell carcinoma9 and preinvasive Bowen's disease has yielded excellent cosmetic results10.
Another potential application is urothelial disease, again because of the limitations of conventional treatments, with which over half of patients with superficial bladder tumours will have recurrences and one-third with carcinoma-in-situ do not respond. The uptake of some photosensitizers by hyperproliferating tissue and the observation that photodynamic therapy can cause vascular stasis have prompted applications in benign conditions. Senile macular degeneration, associated with macular neovascularization, is the leading cause of blindness in the UK. Currently, the accepted treatment is laser photocoagulation but this causes adjacent thermal damage to the retina. Benzoporphyrin derivative (BPD-MA, Verteporfin) photodynamic therapy offers selectivity since at the time of illumination the photosensitizer is still predominantly within the neovasculature. Light is delivered via a slit-lamp to the eye shortly after systemic injection of BPD-MA. The light dose is usually delivered within one minute and only topical anaesthesia is required20.
Restenosis after coronary angioplasty arises from fibrocellular intimal hyperplasia and no drugs have been clinically effective in reducing its incidence. The possible value of photodynamic therapy (with ALA or BPD-MA) is now being explored in clinical trials after success in rat models21.
Psoriasis is commonly treated with ultraviolet light after administration of a psoralen, but an alternative is photodynamic therapy with a topical photosensitizer22. There is some evidence that photodynamic therapy can lessen the pain of psoriatic arthritis as well as improving the skin lesions, perhaps by reducing the number of activated T cells and thereby the autoimmune response23. With certain lesions we are at present unable to illuminate the key area adequately. Infrared, with its long lightwaves, should offer better penetration; so we should be able to apply non-visible radiation in deep anatomical sites without the need for interstitial light fibres.
In short, photodynamic therapy has the potential to become an important modality in the treatment of a broad spectrum of conditions in the twenty-first century.
